Story perspectives

Novartis Raises 2026 Profit Outlook After Q3 Beat

By Drooid · Oct 27, 2026, 22:18 UTC · How we work

Read the story

Story summary

Summary

Novartis raised its full-year 2026 core operating income outlook after Q3 results.
Core operating income climbed 11% to $6.036 billion in Q3 2026.
Core earnings per share rose to $2.46, beating the $2.27 consensus.
Novartis shares rose 1.36% to $155.91 after the upgraded profit outlook.
Net sales grew 4% to $14.522 billion, slightly missing the $14.582 billion estimate.

Summary

The European Commission approved Novartis’ Cosentyx for polymyalgia rheumatica on October 21, 2026.
Novartis held an investor call on remibrutinib for multiple sclerosis on October 23, 2026.
Bernstein analyst Justin Smith kept a Hold rating and set a CHF 132.84 price target on October 27, 2026.
Novartis shares closed at EUR 139.69, 1.89% above the Xetra price of EUR 137.10 on October 27, 2026.

History

In January 2015 the FDA approved Novartis’s secukinumab (Cosentyx) as the first IL-17 inhibitor for moderate-to-severe plaque psoriasis, launching rapid growth. Subsequent approvals for ankylosing spondylitis (2016) and scalp psoriasis (2018) helped the drug reach $1.5 billion worldwide sales by 2018. The European Commission’s October 2026 authorization for polymyalgia rheumatica repeats this expansion pattern.

1 of 3

Historical Context

In January 2015 the FDA approved Novartis’s secukinumab (Cosentyx) as the first IL-17 inhibitor for moderate-to-severe plaque psoriasis, launching rapid growth. Subsequent approvals for ankylosing spondylitis (2016) and scalp psoriasis (2018) helped the drug reach $1.5 billion worldwide sales by 2018. The European Commission’s October 2026 authorization for polymyalgia rheumatica repeats this expansion pattern.

1 / 3